|
[Use of intravenous polyclonal immunoglobulins in autoimmune and inflammatory disorders.]
Transfus Clin Biol. 2007 May 9
[Article in French]
Graff-Dubois S, Siberil S, Elluru S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayary J, Kaveri SV.
Inserm
U 872, universite Rene-Descartes (Paris-5), universite
Pierre-et-Marie-Curie (UPMC Paris-6) et equipe 16 (immunopathologie et
immunointervention therapeutique), centre de recherche des Cordeliers,
Inserm UMR s 872, 15, rue de l'Ecole-de-Medecine, 75006 Paris, France.
Initially
used for the treatment of immunodeficiencies, intravenous
immunoglobulins (IVIg) have increasingly been used as immunomodulatory
agent in autoimmune and inflammatory disorders. The mode of action of
IVIg is enigmatic, probably involving Fc-dependent and/or
F(ab')2-dependent non-exclusive mechanisms of action. IVIg broadly
interacts with the different components of the immune system:
cytokines, complement, Fc receptors and several cell surface
immunocompetent molecules. IVIg also has an impact on effector
functions of immune cells. These mechanisms of action of IVIg reflect
the importance of natural antibodies in the maintenance of immune
homeostasis. We discuss here the recent advances in the understanding
of immunoregulatory effects of IVIg, and we pointed out the need of new
strategies to overcome the predicted increasing worldwide shortage of
IVIg.
|
